Background: Guidelines recommend a combination of inhaled corticosteroids and long-acting bronchodilators in patients with severe COPD. However, recent evidence has raised concerns about the increased risk of pneumonia in patients on inhaled steroids. The exact nature of this association and its specificity to the inhaled corticosteroid component is unclear.
Study design: Meta-analysis and systematic review of 18 randomized controlled trials (RCTs) evaluating inhaled corticosteroid use in COPD.
Setting: Medline, EMBASE, the Cochrane Database of Systematic Reviews, regulatory documents, and trial registries.
Synopsis: This study, which totaled 16,996 case reviews, focused on inhaled corticosteroid use in COPD (excluding asthma) with at least 24 weeks of followup. The study authors evaluated inhaled corticosteroid use—alone or in combination with long-acting beta-agonists (LABA)—against a control (placebo or LABA alone). Primary outcomes were any pneumonia and serious pneumonia leading to increased morbidity and mortality. Secondary outcomes included pneumonia-related mortality and all-cause mortality.
Inhaled corticosteroids—irrespective of associated LABA use—significantly increased the risk of pneumonia (7.4% vs. 4.7%) with a relative risk (RR) of 1.60; 95% CI, 1.33-1.92, P<0.001. Inhaled corticosteroids were strongly associated with an increase in serious pneumonia (RR 1.71; 95% CI, 1.46-1.99, P<0.001). However, inhaled corticosteroid use did not translate to significantly increased pneumonia-related or overall mortality, possibly due to the inadequate power of most of the individual trials.
The findings reflect those from other database studies, but lend specificity to the inhaled corticosteroid component. This can be cause for concern as studies of long-term inhaled corticosteroid use in patients with COPD have failed to show a benefit in mortality or decreased exacerbations.
Bottom line: Risk-benefit analysis for inhaled corticosteroid use in COPD patients should consider the increased risk of pneumonia, possibly related to local immunosuppression.
Citation: Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169(3):219-229.
Inadequate Physician Communication Regarding Dietary Supplement Usage
Clinical question: How frequently do hospital physicians communicate about the use of dietary supplements?
Background: About 20% of the U.S. population uses dietary supplements, products that have potential interactions with other prescription medications. Dietary supplement usage patterns, disclosure, and discussion with physicians have been studied in the outpatient setting. However, these metrics have not been evaluated in the inpatient setting.
Study design: A cross-sectional, observational pilot study.
Setting: Inpatients on a general medicine and geriatrics service at the University of North Carolina Medical Center.
Synopsis: Sixty inpatients were questioned regarding their use of dietary supplements in the past year. Patients were asked about their communication with the admitting resident physician regarding dietary supplements and their beliefs regarding continued use during hospitalization. Patient responses revealed prevalent dietary supplement use, with about 80% of patients using supplements and 52% using nonvitamin/nonmineral supplements.
The study revealed poor communication between residents and their patients. Only 20% of residents inquired about dietary supplement use during the admission process, while 74% of patients neglected to disclose their use of dietary supplements. Furthermore, 56% of patients thought communication was unimportant; they assumed that it was in their medical records (18%), or they expected the physician to ask them about it (20%). Though most patients agreed to stop using dietary supplements as inpatients, 13% did not think dietary supplement use was a problem, even if it went against medical advice.
Study limitations include the small sample size and recall bias inherent to the design. It also is likely that more patients using dietary supplements consented for the study, as evidenced by higher prevalence of use.